Transcatheter closure of atrial septal defects.
Transcatheter closure of atrial septal defects has evolved significantly over the last 20 years. Transcatheter closure has replaced surgical closure for the treatment of most secundum atrial septal defectsat the current time. A major reason for this is the lower morbidity of transcatheter closure procedures. Several closure devices have come into clinical use. The Amplatzer septal occluder (AGA Medical Co.) currently has the largest reported experience and subsequently the best-established safety and efficacy features. Clinically challenging situations, such as larger atrial septal defects, atrial septal defects with deficient rims and multiple atrial septal defects, are increasingly being addressed using the transcatheter approach, with improved results. The incidence of most complications has significantly reduced over time, and serious side effects are relatively uncommon. In this review, the literature is summarized regarding the current role of transcatheter closure, the evolution of the different available devices for clinical use and the complications that occur with their use. A comparison is also made with surgical closure techniques.
Gupta
Anuja
A
KEM Hospital, 48/49 Hatkesh Society, Road number 7, Juhu Scheme, Mumbai400 049, India. doctoranuja@yahoo.com
Kapoor
Gaurav
G
Dalvi
Bharat
B
D021721:Balloon Occlusion / Q000295:instrumentation*; D006328:Cardiac Catheterization / Q000379:methods*; D006344:Heart Septal Defects, Atrial / Q000628:therapy*; D006801:Humans